Little House Capital LLC Decreases Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Little House Capital LLC lessened its holdings in Amgen Inc. (NASDAQ:AMGN) by 24.1% during the 1st quarter, Holdings Channel reports. The firm owned 5,456 shares of the medical research company’s stock after selling 1,734 shares during the quarter. Little House Capital LLC’s holdings in Amgen were worth $1,551,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of AMGN. BKM Wealth Management LLC boosted its stake in shares of Amgen by 16.9% during the 1st quarter. BKM Wealth Management LLC now owns 5,928 shares of the medical research company’s stock worth $1,685,000 after purchasing an additional 855 shares during the last quarter. Aviance Capital Partners LLC raised its holdings in Amgen by 33.5% in the 1st quarter. Aviance Capital Partners LLC now owns 31,496 shares of the medical research company’s stock valued at $8,955,000 after acquiring an additional 7,910 shares during the last quarter. Mirador Capital Partners LP boosted its holdings in Amgen by 39.3% in the first quarter. Mirador Capital Partners LP now owns 2,076 shares of the medical research company’s stock valued at $590,000 after acquiring an additional 586 shares during the last quarter. Chapin Davis Inc. raised its holdings in shares of Amgen by 12.6% during the 1st quarter. Chapin Davis Inc. now owns 3,331 shares of the medical research company’s stock valued at $947,000 after buying an additional 372 shares during the period. Finally, Compass Ion Advisors LLC lifted its position in Amgen by 4.1% during the 1st quarter. Compass Ion Advisors LLC now owns 5,192 shares of the medical research company’s stock worth $1,476,000 after acquiring an additional 204 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 2,117 shares of the stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $313.09, for a total value of $662,811.53. Following the transaction, the senior vice president now owns 9,883 shares of the company’s stock, valued at $3,094,268.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.69% of the company’s stock.

Amgen Price Performance

Shares of AMGN traded down $0.97 during mid-day trading on Monday, reaching $311.48. The company had a trading volume of 873,025 shares, compared to its average volume of 2,775,958. The company has a market capitalization of $167.09 billion, a P/E ratio of 44.64, a P/E/G ratio of 2.82 and a beta of 0.58. The company has a debt-to-equity ratio of 11.96, a current ratio of 1.42 and a quick ratio of 0.98. The company’s 50-day moving average is $301.56 and its 200-day moving average is $292.30. Amgen Inc. has a twelve month low of $218.44 and a twelve month high of $329.72.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share for the quarter, beating analysts’ consensus estimates of $3.76 by $0.20. Amgen had a return on equity of 156.21% and a net margin of 12.74%. The company had revenue of $7.45 billion during the quarter, compared to analyst estimates of $7.45 billion. During the same period last year, the company posted $3.98 earnings per share. The firm’s quarterly revenue was up 22.0% compared to the same quarter last year. On average, equities analysts anticipate that Amgen Inc. will post 19.47 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on AMGN shares. TD Cowen lowered their price target on shares of Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a report on Wednesday, April 17th. Royal Bank of Canada lifted their target price on Amgen from $328.00 to $332.00 and gave the stock an “outperform” rating in a research report on Friday, June 14th. William Blair upgraded Amgen from a “market perform” rating to an “outperform” rating in a research note on Friday, May 3rd. Raymond James initiated coverage on Amgen in a report on Thursday, March 28th. They set a “market perform” rating for the company. Finally, BMO Capital Markets lifted their price objective on shares of Amgen from $336.00 to $355.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. Ten equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Amgen presently has an average rating of “Moderate Buy” and a consensus price target of $307.35.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.